Showing 1 - 20 results of 6,596 for search '(( third ((((larger decrease) OR (_ decrease))) OR (nn decrease)) ) OR ( has a decrease ))', query time: 0.76s Refine Results
  1. 1

    Third. by Cuicui Liu (1496260)

    Published 2024
    “…It revealed that the total systematic spillover exhibited an initial increase, followed by a subsequent decrease. Notably, the fluctuation in this phenomenon intensified significantly during the epidemic. …”
  2. 2
  3. 3
  4. 4

    Table 3_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.xlsx by Aihua Guo (13267712)

    Published 2025
    “…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
  5. 5

    Table 1_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

    Published 2025
    “…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
  6. 6

    Table 2_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

    Published 2025
    “…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”
  18. 18

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”
  19. 19

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”
  20. 20